Outcomes of Oral Vinorelbine in Progressive Desmoid Fibromatosis-Response
Clin Cancer Res
.
2021 Apr 1;27(7):2120.
doi: 10.1158/1078-0432.CCR-21-0041.
Authors
Olivier Mir
1
,
Charles Honoré
2
,
Ali N Chamseddine
3
,
Matthieu Faron
2
,
Leila Haddag-Miliani
4
,
Arnaud Bayle
5
,
Axel Le Cesne
3
Affiliations
1
Department of Ambulatory Cancer Care, Gustave Roussy Cancer Institute, Villejuif, France. olivier.mir@gustaveroussy.fr.
2
Department of Surgery, Gustave Roussy Cancer Institute, Villejuif, France.
3
Department of International Patients Care, Gustave Roussy Cancer Institute, Villejuif, France.
4
Department of Medical Imaging, Gustave Roussy Cancer Institute, Villejuif, France.
5
Department of Ambulatory Cancer Care, Gustave Roussy Cancer Institute, Villejuif, France.
PMID:
33795374
DOI:
10.1158/1078-0432.CCR-21-0041
No abstract available
Publication types
Letter
Comment
MeSH terms
Antineoplastic Combined Chemotherapy Protocols
Desmoid Tumors* / drug therapy
Humans
Vinorelbine / therapeutic use
Substances
Vinorelbine